FHD-609

Names

[ Name ]:
FHD-609

Biological Activity

[Description]:

FHD-609 is an inhibitor and a degrader of BRD9 (bromodomain-containing protein 9). FHD-609 targets to ncBAF, can be used for research of wide range of cancers that contain a mutation in a BAF complex subunit. FHD-609 in combination with Telomelysin or INO5401, may play a role in adrenocortical carcinoma (ACC) treatment[1][2].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Epigenetics >> Epigenetic Reader Domain

[Target]

BRD9

[References]

[1]. Rechberger JS, et al. Atypical teratoid rhabdoid tumor (ATRT): disease mechanisms and potential drug targets. Expert Opin Ther Targets. 2022 Mar;26(3):187-192.

[2]. Hescheler DA, et al. Targeted Therapy for Adrenocortical Carcinoma: A Genomic-Based Search for Available and Emerging Options. Cancers (Basel). 2022 May 31;14(11):2721.

Chemical & Physical Properties

[ Molecular Formula ]:
C₄₇H₅₆N₈O₆

[ Molecular Weight ]:
829.00

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.